Forte's FB-401 Fails to Meet Primary Endpoints in P-II Clinical Trial For the Treatment of Atopic Dermatitis
Shots:
- The P-II clinical trial evaluates FB-401 vs PBO in patients with AD
- The trial did not meet its 1EPs of EASI-50 (50% improvement in AD disease severity as measured by EASI)
- Additionally- positive trends were identified in key 2EPs i.e.- improvement in disease severity @16wks.- patients achieving the EASI-90 EPs (27.6% vs 20.5%) while (38.2% vs 29.5%) in IGA success (2 point reduction and clear or almost clear). The 1EPs of EASI-50 was achieved in 58% vs 60% of patients
| Ref: Business Wire | Image: Forte Bioscience
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com